Pathogenesis of hepatitis C virus

DOI Web Site PubMed 3 Citations 82 References
  • MORIISHI Kohji
    Department of Molecular Virology Research Institute for Microbial Diseases, Osaka University
  • MATSUURA Yoshiharu
    Department of Molecular Virology Research Institute for Microbial Diseases, Osaka University

Bibliographic Information

Other Title
  • Ｃ型肝炎ウイルスの病原性発現機構
  • Cガタ カンエン ウイルス ノ ビョウゲンセイ ハツゲン キコウ

Search this article

Abstract

Hepatitis C virus (HCV) infects approximately 170 million people worldwide including 2 million in Japan and induces serious chronic hepatitis that results in the development of steatosis, cirrhosis and ultimately hepatocellular carcinoma. The current combination therapy using pegylated interferon alpha and a nucleotide analogue ribavirin achieved a sustained virological response in about half population of individuals infected with HCV genotypes 1a and 1b. More than two-thirds of the HCV-positive population has been chronically infected with genotype 1 in Western countries and Japan. Therefore, more effective therapeutics and preventative measures are needed for the treatment of hepatitis C patients who are not responsive to the current chemotherapy. HCV core protein is well known to be the viral capsid protein as well as the pathogenic factor that induces steatosis and hepatocellular carcinoma in the transgenic mice. In this review, we summarize the current status of our knowledge regarding the molecular mechanism by which HCV core protein induces liver steatosis and hepatocellular carcinoma and discuss on a future perspective for the development of novel therapeutics for chronic hepatitis C.

Journal

  • Uirusu

    Uirusu 57 (2), 141-149, 2007

    The Japanese Society for Virology

Citations (3)*help

See more

References(82)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top